Gain Therapeutics Inc. Common Stock (GANX)

About GANX

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

20

Website

www.gaintherapeutics.com/

Fundamentals

1-day range

$1.78$1.85

Market cap

$75.92M

P/E (trailing)

—

P/E (forward)

-3.03

EPS (trailing)

$-0.60

Dividend yield

—

Beta

0.16

Avg. volume

860.8K

Forecasts

5 analyst ratings

Gain Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• GANX

  Gain Therapeutics Inc. Common Stock

  $1.78

  ▼ 3.78%
  Market cap $75.92MP/E —
  $1.53$4.34
• NMAD

  Nomad Power Solutions Inc. Common Stock

  $4.33

  ▼ 2.04%
  Market cap $75.50MP/E —
  $3.12$7.7
• OSTX

  OS Therapies Incorporated Common Stock

  $1.64

  ▼ 2.38%
  Market cap $74.23MP/E —
  $1.15$2.54
• ACET

  Adicet Bio Inc. Common Stock

  $9.05

  ▲ 0.44%
  Market cap $74.13MP/E —
  $6.01$17.44
• SPRO

  Spero Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $73.53MP/E 4.73
  $1.08$3.08
• ACRV

  Acrivon Therapeutics Inc. Common Stock

  $2.06

  ▼ 4.19%
  Market cap $72.33MP/E —
  $1.27$3.56
• ELTX

  Elicio Therapeutics Inc. Common Stock

  $2.86

  ▼ 4.67%
  Market cap $72.28MP/E —
  $2.66$16

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
  Benzinga · 8/11/2026

• Khalid Islam · July 15, 2026 · Grant

  25.0K
• Claude Nicaise · July 15, 2026 · Grant

  25.0K
• Gwen A. Melincoff · July 15, 2026 · Grant

  25.0K
• Jeffrey Scott Riley · July 15, 2026 · Grant

  25.0K
• HASLER HANS PETER · July 15, 2026 · Grant

  25.0K
• Dov A. Goldstein, MD · July 15, 2026 · Grant

  25.0K
• Fuggetta Gianluca · March 24, 2026 · Grant

  50.0K
• Gene Mack · March 24, 2026 · Grant

  200.0K

Institutional Ownership

March 31, 2026

Total shares held

8.05M

Total value held

$13.81M

Institutional holders

38